Patient-selected goals in overactive bladder: A placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence

BJU International

Volumn 107, Issue 1, 2011, Pages 70-76

  Cartwright, Rufus ^a   Srikrishna, Sushma ^a   Cardozo, Linda ^a   Robinson, Dudley ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

overactive bladder; Oxybutynin; patient goals; transdermal; urgency urinary incontinence; urinary urgency

Indexed keywords

OXYBUTYNIN; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MICTURITION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE; TRANSDERMAL PATCH; TREATMENT DURATION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; VISUAL ANALOG SCALE; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; GOALS; HUMANS; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT PARTICIPATION; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 78650668638     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09508.x     Document Type: Article

References (50)

1. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D,. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62
2. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J,. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; 4: CD003781
3. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S,. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93
4. Salvatore S, Khullar V, Cardozo L, Milani R, Athanasiou S, Kelleher C,. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 2005; 119: 237-41
5. Lawrence M, Guay DR, Benson SR, Anderson MJ,. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20: 470-5
6. Yu YF, Nichol MB, Yu AP, Ahn J,. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 2005; 8: 495-505
7. Brostrøm S, Hallas J,. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009; 65: 309-14
8. Hall SA, Link CL, Hu JC, Eggers PW, McKinlay JB,. Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. BJU Int 2009; 104: 1680-8
9. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008; 102: 774-9
10. Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared with immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140-5
11. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
12. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237-42
13. Cartwright R, Cardozo L,. Transdermal oxybutynin: sticking to the facts. Eur Urol 2006; 51: 907-14
14. Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A,. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS ONE 2007; 2: e195
15. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ,. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
16. Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006; 50: 1050-7
17. DuBeau CE, Khullar V, Versi E,. 'Unblinding' in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn 2005; 24: 13-20
18. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW,. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263-70
19. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 335-40
20. Chapple CR, Cardozo L, Steers WD, Govier FE,. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006; 60: 959-66
21. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-15
22. Tapp AJ, Cardozo LD, Versi E, Cooper D,. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 521-6
23. Moore KH, Goldstein M, Hay D,. The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 1063-4
24. Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K,. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 646-51
25. Landis JR, Kaplan S, Swift S, Versi E,. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004; 171: 752-6
26. Haab F, Stewart L, Dwyer P,. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-9
27. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
28. Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM,. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004; 93: 71-7
29. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24
30. Mattiasson A, Masala A, Morton R, Bolodeoku J,. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. BJU Int 2010; 105: 1126-35
31. Cartwright R, Cardozo L,. Measuring overactive bladder syndrome symptoms. In, Krieder K, Dmochowski R, eds. The Overactive Bladder: Evaluation and Management, London: Informa Healthcare, 2007: 37-50
32. Brubaker L, Chapple C, Coyne KS, Kopp Z,. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006; 68: 3-8
33. Hróbjartsson A, Gøtzsche PC,. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004; 256: 91-100
34. Brubaker L, Shull B,. EGGS for patient-centered outcomes. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 171-3
35. Marschall-Kehrel D, Roberts RG, Brubaker L,. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006; 68: 29-37
36. Choo MS, Doo CK, Lee KS,. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract 2007; 62: 191-6
37. Lowenstein L, Fitzgerald MP, Kenton K, et al. Patient-selected goals: the fourth dimension in assessment of pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 2007; 19: 81-4
38. UCB Pharma. Kentera-Summary of Product Characteristics. Available at:. Accessed 1 June 2010
39. Lowenstein L, Kenton K, Pierce K, Fitzgerald MP, Mueller ER, Brubaker L,. Patients' pelvic goals change after initial urogynecologic consultation. Am J Obstet Gynecol 2007; 197: 640.e1-3
40. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78 (Pubitemid 34195211)
41. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2009; 29: 4-20
42. Cardozo L, Heßdörfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 1120-7
43. Cartwright R, Panayi D, Cardozo L, Khullar V,. Reliability and normal ranges for the Patient's Perception of Intensity of Urgency Scale in asymptomatic women. BJU Int 2009; 105: 832-6
44. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S,. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-79
45. Reese PR, Pleil AM, Okano GJ, Kelleher CJ,. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003; 12: 427-42
46. Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH,. How much is enough and who says so? BJOG 2004; 111: 605-12
47. Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M,. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int 2008; 102: 208-13
48. Hullfish KL, Bovbjerg VE, Gibson J, Steers WD,. Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol 2002; 187: 88-92
49. Hullfish KL, Bovbjerg VE, Steers WD,. Patient-centered goals for pelvic floor dysfunction surgery: long-term follow-up. Am J Obstet Gynecol 2004; 191: 201-5
50. Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84